Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer - Adventist HealthCare

Skip to Content

Clinical Trial Details


Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer


Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Ovarian Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 05/19/2016
Study Completion Date: 09/06/2019

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy.

The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

NCT Number
Principal Investigator(s)
Frederick Min, MD
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Female


  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 100k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!